Lamotrigine (All indications)

Club foot / Talipes equinovarus

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S15197
R62331		 Cohen (Lamotrigine) (Mixed indications), 2023 Clubfoot 1st trimester population based cohort retrospective unexposed (general population or NOS) Adjustment: Yes Partial overlapping 1.04 [0.69;1.56] -/8,339   -/4,866,362 - 8,339
ref
S10035
R36169		 Blotière (Lamotrigine) (Mixed indications), 2019 Talipes equinovarus 1st trimester retrospective cohort (claims database) unexposed (general population or NOS) Adjustment: No 0.70 [0.10;2.70] 2/2,997   1,677/1,875,733 1,679 2,997
ref
S8971
R30406		 Dolk (Lamotrigine) (Mixed indications), 2016 All clubfoot 1st trimester case control unexposed (general population or NOS) Adjustment: Yes 1.60 [0.81;3.15] 9/   -/- - 0
ref
S8908
R30106		 Källén (Lamotrigine) (Indications NOS), 2013 Pes equinovarus early pregnancy population based cohort retrospective unexposed (general population or NOS) Adjustment: No Partial overlapping 0.68 [0.10;4.86] C 1/1,084   2,127/1,575,847 2,128 1,084
ref
Total 4 studies 1.12 [0.80;1.57] 3,807 12,420
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Cohen (Lamotrigine) (Mixed indications), 2023Cohen, 2023 1 1.04[0.69; 1.56]-8,33968%ROB confusion: seriousROB selection: lowROB classification: moderateROB missing: unclearROB mesure: moderateROB reporting: moderate Blotière (Lamotrigine) (Mixed indications), 2019Blotière, 2019 2 0.70[0.10; 2.70]1,6792,9974%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Dolk (Lamotrigine) (Mixed indications), 2016Dolk, 2016 3 1.60[0.81; 3.15]--25%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Källén (Lamotrigine) (Indications NOS), 2013Källén, 2013 4 0.68[0.10; 4.86]2,1281,0843%ROB confusion: criticalROB selection: moderateROB classification: moderateROB missing: unclearROB mesure: moderateROB reporting: moderate Total (4 studies) I2 = 0% 1.12[0.80; 1.57]3,80712,4200.25.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Lamotrigine) (Mixed indications; 2: Lamotrigine) (Mixed indications; 3: Lamotrigine) (Mixed indications; 4: Lamotrigine) (Indications NOS;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.00[0.68; 1.48]3,80712,4200%NACohen (Lamotrigine) (Mixed indications), 2023 Blotière (Lamotrigine) (Mixed indications), 2019 Källén (Lamotrigine) (Indications NOS), 2013 3 case control studiescase control studies 1.60[0.81; 3.16]-- -NADolk (Lamotrigine) (Mixed indications), 2016 1 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 1.12[0.80; 1.57]3,80712,4200%NACohen (Lamotrigine) (Mixed indications), 2023 Blotière (Lamotrigine) (Mixed indications), 2019 Dolk (Lamotrigine) (Mixed indications), 2016 Källén (Lamotrigine) (Indications NOS), 2013 4 Tags Adjustment   - No  - No 0.69[0.20; 2.45]3,8074,0810%NABlotière (Lamotrigine) (Mixed indications), 2019 Källén (Lamotrigine) (Indications NOS), 2013 2   - Yes  - Yes 1.18[0.80; 1.73]-8,33912%NACohen (Lamotrigine) (Mixed indications), 2023 Dolk (Lamotrigine) (Mixed indications), 2016 2 Partial overlappingPartial overlapping 1.02[0.69; 1.52]2,1289,4230%NACohen (Lamotrigine) (Mixed indications), 2023 Källén (Lamotrigine) (Indications NOS), 2013 2 All studiesAll studies 1.12[0.80; 1.57]3,80712,4200%NACohen (Lamotrigine) (Mixed indications), 2023 Blotière (Lamotrigine) (Mixed indications), 2019 Dolk (Lamotrigine) (Mixed indications), 2016 Källén (Lamotrigine) (Indications NOS), 2013 40.25.01.0

Publication bias and p-hacking diagnosis

funnel plot
0.0-2.42.51.2010.000Cohen (Lamotrigine) (Mixed indications), 2023Blotière (Lamotrigine) (Mixed indications), 2019Dolk (Lamotrigine) (Mixed indications), 2016Källén (Lamotrigine) (Indications NOS), 2013

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot
0.01.00.01.0

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.12[0.80; 1.57]3,80712,4200%NACohen (Lamotrigine) (Mixed indications), 2023 Blotière (Lamotrigine) (Mixed indications), 2019 Dolk (Lamotrigine) (Mixed indications), 2016 Källén (Lamotrigine) (Indications NOS), 2013 40.510.01.0

Umbrella review (other published meta-analyses)

Published MATE95% CIn exposedkI2Control groupExposition period Veroniki (NMA)Veroniki (NMA) 0.70[0.12; 2.89]-whatever (meta-analysis)during pregnancy (anytime or not specified)studies4 metaPregmetaPreg 1.12[0.80; 1.57]0%12,420--Cohen (Lamotrigine) (Mixed indications), 2023 Blotière (Lamotrigine) (Mixed indications), 2019 Dolk (Lamotrigine) (Mixed indications), 2016 Källén (Lamotrigine) (Indications NOS), 2013 40.510.01.0